Trial Profile
Hyperfractionated radiotherapy with cisplatin or cetuximab in advanced non-metastatic head and neck cancer, a phase II/III randomised study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 30 Jul 2014
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 21 Jun 2012 New trial record
- 05 Jun 2012 Preliminary results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.